Stratulat Albulescu advises Walden Group on the acquisition of Romanian transport company Alex International Transport 94

A Corporate and M&A Group at SAA advised Walden Group - the European leader in transport in healthcare - on its acquisition of the Romanian target.

The acquisition of Alex Transport follows Walden’s’ strategy to expand and continue its growth in other European territories with a view to make best use of cross recommendation to existing clients once the last mile network for direct deliveries to Pharmacies and Hospitals comes to life.

Alex International Transport 94 S.R.L. is a Romanian transportation company specialized in road freight forwarding.

Walden Group is a family-owned group with a European coverage ensured by more than 5,000 people across 12 European countries.

The Stratulat Albulescu team was led by both Silviu Stratulat (Managing Partner) and Raluca Gabor (Managing Associate) with the close support of Associate Amanda Csaki and Partner Tudor Ciambur and Associate Irina Caragea.

Thanks to a unique network in Romania, consisting of 35 GDP-certified cross-docking sites and more than 150 employees, Alex International Transport offers access to a last mile distribution network in Romania that complies with Good Distribution Practices and the quality criteria of its customers.

Benoît Latteur, CEO of Eurotranspharma, says, “With this acquisition, we continue to develop our offer in Europe. This is a rapidly evolving market with ever more demanding needs in terms of healthcare product supply. The reach of our network is a key element in meeting this growing demand. I have full confidence in Alexandru and his teams to accompany us in this new phase of our network’s development”.

Alexandru Constantinescu, founder and CEO of Alex International Transport, said: “For 30 years, we have been developing a network with expertise, added value, and innovative capacity that is unique in Romania. I am pleased to see our company take a new step forward by becoming part of a long-term European project, which is essential for our development. Beyond new access to an expert network and to Eurotranspharma’s innovative tools, the connection with our colleagues from other European countries will be a major asset in our growth. I am looking forward to this new step”.